George, it's a silly argument. Kevetrin is nearing the end of a Phase I trial. The primary endpoints of defining MTD and DLT will soon be defined. Secondary outcome measures including pharmacokinetic profile, change in tumor size, change in tumor markers, and changes in P21 biomarker will be achieved. It's a lot of information that will allow for Phase II strategy to optimize dosing, better define target patient population, and allow better insight into Kevetrin's potential as an anti-cancer agent.
Do you believe that eventual use of Kevetrin as monotherapy or in combination therapy impacts Cellceutix's valuation at this time? IMO, Kevetrin as a single agent would be great and I'd be very happy. And if another agent can be combined with Kevetrin to give even a slight benefit to a cancer patient, I'm all for it. It's no longer monotherapy but it's better for the patient. If Kevetrin can be used in combination with other agents for a wide variety of cancers then I'm thrilled. What's best for investors? If Kevetrin is eventually approved, they're all homeruns.
We have a long way to go in clinical trials and its eventual use as monotherapy or in combination does not impact my investment decision in any way. I'd be surprised if monotherapy vs. combination therapy for Kevetrin impacts the decisions of any investors at this stage.
Declaring an opinion over and over again does not make it fact.
btw, I note that you still haven't answered DrBones question about p21 levels that are necessary for substantial benefit. Good luck finding the answer and please let us know.
